{
  "id": 20736831,
  "title": "London-based Boltz raises $110M Series A",
  "url": "https://urgent.news/2026/11/19/london-based-boltz-raises-110m-series-a",
  "topic": "business",
  "section": "Business",
  "published": "2026-11-19T10:04:00.000Z",
  "source": {
    "name": "Tech.eu",
    "slug": "tech-eu",
    "url": "https://tech.eu/2026/11/19/london-based-boltz-raises-110m-series-a/"
  },
  "original_language": "en",
  "account": "AI drug discovery startup Boltz has secured $110 million in Series A funding, marking a significant investment less than a year after leaving stealth mode. The London-based company, now based in King's Cross, employs 40 AI researchers dedicated to accelerating the drug discovery process. Lead investor Bessemer Venture Partners joined a roster of existing backers, including Andreessen Horowitz, Amplify Partners, Zetta Venture Partners, and Obvious Ventures. Additional investors comprised Greycroft, F-Prime Capital, Hummingbird, and Benchling, alongside Nvidia, which also announced a separate investment during Jensen Huang's UK visit.\n\nBoltz's software assists pharmaceutical and biotech researchers in designing potential drugs and determining which candidates to test in laboratories. The company's AI models can predict protein-drug interactions, estimate binding strength, and propose new molecules tailored to target proteins. The firm offers both open-source models and proprietary ones via its platform and API, setting a default option for early-stage drug discovery research.\n\nMIT co-founders previously released open-source models comparable to closed-source alternatives like DeepMind's AlphaFold3. Now integrated into Boltz's platform, these models are widely adopted in the industry. The company has forged partnerships with Pfizer, GSK, Takeda, and Bristol Myers Squibb. Revenue stems from collaborations and platform access. Boltz plans to allocate the new funding towards enhancing computational resources, data infrastructure, and team expansion.\n\nIn their statement, Boltz expressed confidence in the rapid advancements in AI models, anticipating significant improvements in molecule generation quality. The company's long-term objective remains the realization of a system enabling scientists to progress from therapeutic concepts directly to human-ready drugs, all without leaving their computers. Achieving this vision necessitates further model developments and substantial investment in compute and data resources.",
  "summary": "London-based AI drug discovery startup Boltz has raised a $110m Series A funding round, less than a year after emerging out of stealth.Boltz is an AI research startup that develops AI models to speed ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}